Celina V. Malyar, Boldizsar Kovacs, Bakhtawar K. Mahmoodi, Andreas Haeberlin, Tobias Reichlin, Sing-Chien Yap
A novel dual-energy lattice-tip catheter (Sphere-9, AFFERA, Medtronic) has shown promising results for the treatment of refractory ventricular arrhythmias. The multicenter AFFERA Ventricular Arrhythmia Ablation (AVAAR) registry demonstrated the feasibility and safety of ventricular tachycardia (VT) ablation using the lattice-tip catheter.1 However, there is limited data on the safety of the AFFERA system in patients with cardiac implantable electronic devices (CIED). There is emerging data that both radiofrequency ablation (RFA) and pulsed field ablation (PFA) delivered with the lattice-tip catheter may cause inadvertent effects during VT ablation.